AZNAstraZenecaFinished
Study of AZD9829 in CD123+ Hematological Malignancies
Hematological Malignancies
10Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +10
Main results were due Oct 2025, none posted yet
Counts until it's fixed
Worry score10
Score over time
- Stage
- Phase 1/2
- Patients
- 56 (final count)
- Started
- Jan 31, 2024
- Main results expected
- Oct 31, 2025
- Fully finished
- Feb 24, 2026
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Frequency of dose limiting toxicities (DLTs).
Measured over: Module 1 - 28 days.
Safety evaluation of AZD9829: Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
Measured over: Module 1 - From informed consent until 60 days after last dose of AZD9829.
Identify RP2D in R/R AML patients.
Measured over: Moldule 1 -From informed consent until 60 days after last dose of AZD9829.
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- results_overdue: base 10, now 10, since 2025-10-31, no fading
Raw record changes
- none yet
Trial ID NCT06179511 · record last updated 2026-07-01 · checked 2026-11-09 15:47 UTC